Pomalidomide (Pomalidomide Celgene®) has been granted a licence for use in myeloma patients across Europe.
This decision by the European Commission follows the positive recommendation in May 2013 for pomalidomide by the Committee for Medicinal Products for Human Use (CHMP), within the European Medicines Agency (EMA). Continue reading
The European Commission granted a licence for the use of two new indications of Velcade® (bortezomib) in the treatment of myeloma. It has approved its use as an induction treatment for newly diagnosed patients prior to high-dose therapy and autologous stem cell transplantation and as a retreatment in relapsed myeloma patients (in combination with thalidomide and dexamethasone) who have previously responded well to Velcade®. Continue reading
Smouldering myeloma patients are generally not treated until symptoms develop. The current standard of care is observation.
Previous attempts at treating smouldering myeloma with older treatments such as alkylating agents either were not effective or led to concerns about long-term toxicity. Continue reading
Statistically significant improvement in progression-free survival demonstrated
On Thursday 11 July 2013, Celgene International Sàrl announced that its phase III study (MM-020/IFM 07-01) of REVLIMID® (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival (PFS). In the study, a doublet regimen of continuous oral lenalidomide in combination with low-dose dexamethasone (Rd) demonstrated a statistically significant improvement in PFS compared to patients receiving a comparator arm with a triplet regimen consisting of melphalan, prednisone and thalidomide (MPT). Continue reading
We are delighted to anounce that the MPE report on Myeloma Patient Perspectives is being launched today, Friday 14 June 2013.
Printed copies are available at EHA 2013 in Stockholm.
Please feel free to pick up a copy at the EHA MPE booth (table top C14:11) from 14-16 June 2013.
For more information on these report, please send an email to info@myelomapatientseurope.org
MPE will be represented by several delegates at the 18th EHA congress in Stockholm (13-16 June 2013).
We also have a booth where printed versions of our key documents and recent publications will be provided, such as the MPE report on Myeloma Patient Perspectives, the executive summary of the report, a summary of our strategic plan 2013-2018 and the Clinical Trial Charter developed by MPE. Continue reading
The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for Pomalidomide (Pomalidomide Celgene®) in the treatment of multiple myeloma for relapsed and refractory myeloma patients. The next step is for the European Commission to adopt the final licensing decision within three months. There is no doubt that this is a crucial step for patients within the EU towards getting access to pomalidomide in their national health systems. Continue reading
The MC held in Madrid on 13 April 2013 was a great success.
We had the honour to have with us some highly qualified speakers who specialise in personalised medicine. Also the ethical implications of personalised medicine were discussed in depth. Continue reading
Madrid, Saturday 13 April 2013 (9:00am – 4:30pm)
After the success of MPe’s I Masterclass that took place in Edinburgh last year, the second one will follow this spring focusing on myeloma genetics and the role of bio banks. The issue will be presented and discussed from a medical point of view, but also from the patient perspective, particularly concerning the ethical issues involved in these kind of treatments. Continue reading
On the 12 March Aeterna Zentaris announced the discontinuation of their Phase III myeloma study of perifosine subsequent to a recommendation by the Data Safety Monitoring Board (DSMB).
According to the DSMB, the pre-planned interim analysis of efficacy and safety indicates that the study may not reach the significant difference in progression free survival, the primary endpoint. Continue reading